drugset / Trial / NCT04309656

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

NCT04309656

Phase 1 Completed 48 enrolled Global Alliance for TB Drug Development
RandomizedCrossoverOpen-labelTreatment

Summary

This is a single-dose, open-label, randomized, four-period, four-treatment, crossover study in healthy adult subjects.

Timeline

Start
2020-01-14
Primary completion
2020-02-28
Completion
2020-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Pretomanid Small molecule 10 mg Oral
Subject Pretomanid Small molecule 50 mg Oral
Subject Pretomanid Small molecule 200 mg Oral